In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Maquet CV: Old Name, New Emerging Mid-Cap Strategic Acquirer

Executive Summary

After some recent changes – like moving its headquarters to the US and spending $2.3 billion on several recent deals – Maquet is becoming just what the cardiovascular device industry needs: a mid-sized company committed to an aggressive acquisition strategy.

You may also be interested in...

Getinge/Maquet CV Emerging As Mid-Cap Strategic With Atrium Acquisition

At a time when the cardiovascular device industry is seeing less interest in M&A on the part of several large strategic players that formerly were major acquirers, a new mid-cap player appears to be emerging: Getinge's Maquet Cardiovascular division. The company recently announced its third major cardiovascular deal in the last five years with its $680 million acquisition of Hudson, NH-based Atrium Medical, which has a diversified cardiovascular products business.

QUOTED. 12 August 2020. Rep. James Clyburn.

House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.

Zero Gravity Submits To NAD Review For Skin-Rejuvenating Device Claims Following FTC Referral

The Perfectio device marketer came away from the advertising industry’s self-regulatory process with a number of claims intact or mostly untouched, though it discontinued a couple going into the assessment and the National Advertising Division advised against a few others. The firm has pledged to comply “in the spirit of compromise.”


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts